| Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 16176811 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Patients with rheumatoid arthritis (RA) frequently display an atherogenic lipid profile which has been linked with inflammation. Tumor necrosis factor-alpha (TNF-alpha), a pivotal pro-inflammatory cytokine in RA may be involved in the development of the disturbed lipid metabolism. We investigated whether infliximab, an anti-TNF-alpha therapy, may modify the lipid profile. METHODS: 56 consecutive RA patients were treated with infliximab (3 mg/kg at weeks 0, 2, 6, 14, 22, 30). Lipid profile and CRP were assayed at baseline and before infusion at weeks 6 and 30. Baseline values were compared with those in 56 healthy volunteers. RESULTS: At baseline, the concentrations of HDL-cholesterol were lower in RA patients than in the controls (1.3+/-0.4 vs. 1.5+/-0.2 mmol/L; p<0.01). The triglyceride concentrations (1.6+/-0.8 vs. 1.3+/-0.4 mmol/L, p<0.01), the ratio of total cholesterol/HDL-cholesterol (4.3+/-1.6 vs. 3.2+/-0.5, p<0.001) and LDL-cholesterol/HDL-cholesterol (2.6+/-1.2 vs. 1.7+/-0.5, p<0.001) were significantly higher in RA patients than in controls. After 6 weeks of infliximab therapy, the mean total cholesterol concentration increased by 25% (p<0.001), LDL-cholesterol by 24% (p<0.001) and HDL-cholesterol by 30% (p<0.001). The decrease in CRP levels to 30 week inversely correlated with the increase in HDL-cholesterol (r=-0.47, p=0.005). CONCLUSIONS: Infliximab administration is associated with important increases in cholesterol levels in all its forms but as no significant beneficial effect on the atherogenic ratio. |
| | |
Authors:
|
Yannick Allanore; André Kahan; Jeremie Sellam; Ohvanesse G Ekindjian; Didier Borderie |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article Date: 2005-09-19 |
Journal Detail:
|
Title: Clinica chimica acta; international journal of clinical chemistry Volume: 365 ISSN: 0009-8981 ISO Abbreviation: Clin. Chim. Acta Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-02-06 Completed Date: 2006-06-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1302422 Medline TA: Clin Chim Acta Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 143-8 Citation Subset: IM |
Affiliation:
|
Department of Rheumatology A, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Paris 5 University, 75679 Paris Cedex 14, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antibodies, Monoclonal / therapeutic use* Arthritis, Rheumatoid / blood*, drug therapy* Female Humans Lipids / blood* Male Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Lipids; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: PTPase inhibition restores ERK1/2 phosphorylation and protects mammary epithelial cells from apoptos...
Next Document: The formation and rapid clearance of a truncated albumin species in a critically ill patient.